Healthcare Research Analysts
Comprehensive investigation, research and thought are used by our analysts to create the best information and options for our clients.
Paul Knight, CFA
Life Science Technology, Bioproduction & Diagnostics
Paul Knight is a Managing Director, Equity Research Analyst with KeyBanc Capital Markets Inc. His research coverage focuses on Healthcare, specifically the Life Science Technology, Bioproduction & Diagnostics sectors.
Prior to joining KeyBanc Capital Markets in fall 2020, Knight spent seven years as an Equity Research Analyst covering Life Science Technology at Janney, Montgomery & Scott in New York. Before that, he covered Life Science Technology for CLSA (Credit Agricole Securities) for three years. Previous professional experience includes being a founding partner and analyst at Thomas Weisel Partners Group (Stifel Financial), a senior analyst at Salomon Brothers, as well as a political analyst for NatWest Securities in New York and Washington, D.C., covering FDA and Congressional Committee meetings.
Knight earned an M.B.A. in Finance from George Washington University in Washington, D.C., and a B.S. in Economics from the University of Nebraska. He is a Chartered Financial Analyst, and also holds the Series 7, 62, 86 & 87 industry licenses.
Knight has been ranked as a top research analyst multiple times by surveys including Institutional Investor, Greenwich Associates, and The Wall Street Journal. He has delivered keynote addresses for several significant industry events, such as the Analytical & Life Sciences and Industry Association CEO Roundtable and the American Chemical Society’s annual meeting.
Life Science Technology, Bioproduction & Diagnostics Companies under Research Coverage
|Agilent Technologies, Inc.||A|
|Avid Bioservices, Inc.||CDMO|
|BioLife Solutions, Inc.||BLFS|
|Castle Biosciences, Inc.||CSTL|
|Charles River Laboratories International, Inc.||CRL|
|Codex DNA, Inc.||DNAY|
|Harvard Bioscience, Inc.||HBIO|
|IQVIA Holdings Inc.||IQV|
|Lonza Group AG||LONN|
|Maravai LifeSciences Holdings, Inc.||MRVI|
|Medpace Holdings, Inc.||MEDP|
|Mesa Laboratories, Inc.||MLAB|
|Scientific Industries, Inc.||SCND|
|Stevanato Group S.p.A.||STVN|
|Syneos Health, Inc.||SYNH|
|Thermo Fisher Scientific Inc.||TMO|
|West Pharmaceutical Services, Inc.||WST|
Matthew Mishan, CFA
Matthew Mishan is a Vice President, Equity Research Analyst with KeyBanc Capital Markets Inc. His research coverage is focused on medical products companies.
Prior to his promotion to senior analyst, Mishan worked in Equity Research Product Management. Before that, he was a Research Associate on the automotive team for several years. Previous professional experience includes various roles in the financial services industry in Miami.
Mishan earned a Bachelor of Science in Business Administration degree in Finance and Management from the University of Florida in Gainesville, as well as a Master of Business Administration degree in Finance and Capital Markets from the Goizueta Business School at Emory University in Atlanta.
Medical Products Companies under Research Coverage
|Avanos Medical, Inc.||AVNS|
|Baxter International Inc.||BAX|
|Becton, Dickinson and Company||BDX|
|Cooper Company (The)||COO|
|ICU Medical, Inc.||ICUI|
|LeMaitre Vascular, Inc.||LMAT|
|Sotera Health Company||SHC|
KeyBanc Capital Markets is a trade name under which corporate and investment banking products and services of KeyCorp® and its subsidiaries, KeyBanc Capital Markets Inc., Member FINRA/SIPC, and KeyBank National Association (“KeyBank N.A.”), are marketed. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives, who may also be employees of KeyBank N.A. Banking products and services are offered by KeyBank N.A.
Securities products and services: Not FDIC Insured • No Bank Guarantee • May Lose Value
Please read our complete KeyBanc Capital Markets disclosure statement.